Volume 88, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Two formulations of a new live tetravalent dengue virus (DENV) vaccine produced using re-derived master seeds from a precursor vaccine and that same precursor vaccine as a control were compared in a placebo-controlled, randomized, observer-blind, phase II trial of 86 healthy adults. Two vaccine doses were administered 6 months apart; a third dose was offered to a subset. Symptoms and signs of dengue-like illness reported after vaccination were mild to moderate, transient, and occurred with similar frequency among recipients of the new DENV vaccine and placebo, except for rash. Neither dengue nor vaccine-related serious adverse events were reported. The first DENV vaccine dose was moderately immunogenic; the second dose increased the potency and breadth of the neutralizing antibody response. Tetravalent response rates to the new formulations were 60% and 66.7% in unprimed subjects. A third dose did not increase tetravalent antibody rates. The new DENV vaccine candidates merit additional evaluation.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2012. Dengue and severe dengue, Fact sheet N°117. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/index.html Jan 2012.
  2. Thomas S, , 2011. The necessity and quandaries of dengue vaccine development. J Infect Dis 203: 299303.[Crossref] [Google Scholar]
  3. Mustafa MS, Agrawal VK, , 2008. Dengue vaccine: the current status. MJAFI 64: 161164. [Google Scholar]
  4. Pang T, Cardosa MJ, Guzman MG, , 2007. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85: 4345.[Crossref] [Google Scholar]
  5. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DNC, Meltzer MI, , 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 12751280.[Crossref] [Google Scholar]
  6. Innis BL, Eckels KH, , 2003. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69: 14. [Google Scholar]
  7. Edelman R, Wasserman S, Bodison S, Putnak R, Eckels K, Tang D, Kanesa-Thasan N, Vaughn D, Innis B, Sun W, , 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl): 4860. [Google Scholar]
  8. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R, , 2009. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5: 3340.[Crossref] [Google Scholar]
  9. Simasathien S, Thomas SK, Watanaveeradej V, Nisalak A, Barberousse C, Innis B, Sunn W, Putnak R, Eckels K, Hutagalung Y, Gibbons R, Zhang C, De La Barrera R, Jarman R, Chawachalasai W, Mammen M, , 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426433. [Google Scholar]
  10. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, De La Barrera R, Mammen MP, Jr, 2011. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 85: 341351.[Crossref] [Google Scholar]
  11. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH, Jr, 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69 (Suppl): 1216. [Google Scholar]
  12. Lee IK, Lee WH, Liu JW, Yang KD, , 2010. Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients. Int J Infect Dis 14: e919e922.[Crossref] [Google Scholar]
  13. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical Dictionary for Regulatory Activities and Maintenance and Support Services Organization. Version 14.0 01, March 2011. Available at: http://www.meddramsso.com. Accessed March 22, 2012. [Google Scholar]
  14. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V, , 2008. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 153: 16.[Crossref] [Google Scholar]
  15. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W, , 2011. Immunological interference and facilitation between dengue serotypes in tetravalent formulations. J Infect Dis 204: 442450.[Crossref] [Google Scholar]
  16. De La C, Sierra B, Kourí G, Guzmán MG, , 2007. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 152: 533542.[Crossref] [Google Scholar]
  17. Mackowiak PA, Wasserman SS, Tacket CO, Vaughn DW, Eckels KH, Dubois DR, Hoke CH, Edelman R, , 1994. Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines. Clin Infect Dis 19: 948950.[Crossref] [Google Scholar]
  18. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS, , 2000. Human skin Langerhans cells are targets of dengue virus infections. Nat Med 6: 816820.[Crossref] [Google Scholar]
  19. Durbin AP, Karron RA, Sun W, Vaughn D, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai C-J, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, , 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405413. [Google Scholar]
  20. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak AJ, , 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Infect Dis 181: 29.[Crossref] [Google Scholar]
  21. Guy B, Saville M, Lang J, , 2010. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 6: 696705.[Crossref] [Google Scholar]
  22. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, , 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825833.[Crossref] [Google Scholar]
  23. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, , 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370377.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 05 Jun 2012
  • Accepted : 29 Sep 2012
  • Published online : 09 Jan 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error